DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

Search

Ocugen Inc

Uždarymo kaina

1.78 1.71

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.76

Max

1.87

Pagrindiniai rodikliai

By Trading Economics

Pajamos

611K

-15M

Pardavimai

-108K

1.4M

Pelno marža

-1,073.489

Darbuotojai

95

EBITDA

724K

-13M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+367.03% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

250M

568M

Ankstesnė atidarymo kaina

0.07

Ankstesnė uždarymo kaina

1.78

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Ocugen Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-08 20:45; UTC

Uždarbis

Costco Wholesale Sales Climb in September, Early October

2025-10-08 20:12; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

TaskUs Shares Fall After Holders Reject Take-Private Deal

2025-10-08 16:39; UTC

Pagrindinės rinkos jėgos

Mining Shares Rise as Gold Prices Soar

2025-10-08 23:45; UTC

Rinkos pokalbiai

Nikkei May Rise on Weaker Yen -- Market Talk

2025-10-08 23:43; UTC

Rinkos pokalbiai

Gold Falls on Possible Profit-Taking -- Market Talk

2025-10-08 23:18; UTC

Įsigijimai, susijungimai, perėmimai

JD Logistics to Finance Acquisition Using Internal Funds

2025-10-08 23:17; UTC

Įsigijimai, susijungimai, perėmimai

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

2025-10-08 23:16; UTC

Įsigijimai, susijungimai, perėmimai

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

2025-10-08 21:54; UTC

Rinkos pokalbiai
Uždarbis

James Hardie Could Beat Annual Earnings Goal -- Market Talk

2025-10-08 21:30; UTC

Rinkos pokalbiai

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

2025-10-08 21:26; UTC

Rinkos pokalbiai
Uždarbis

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

2025-10-08 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-08 19:15; UTC

Rinkos pokalbiai

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

2025-10-08 19:01; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

2025-10-08 18:47; UTC

Rinkos pokalbiai

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

2025-10-08 18:46; UTC

Įsigijimai, susijungimai, perėmimai

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

2025-10-08 18:46; UTC

Įsigijimai, susijungimai, perėmimai

TaskUs Will Remain a Publicly Traded Co >TASK

2025-10-08 18:46; UTC

Įsigijimai, susijungimai, perėmimai

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

2025-10-08 18:45; UTC

Įsigijimai, susijungimai, perėmimai

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

2025-10-08 18:07; UTC

Rinkos pokalbiai

Mexico's Inflation Seen Edging Up in September -- Market Talk

2025-10-08 16:20; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Energy & Utilities Roundup: Market Talk

2025-10-08 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-08 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-10-08 15:57; UTC

Rinkos pokalbiai

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

2025-10-08 15:56; UTC

Rinkos pokalbiai

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

2025-10-08 15:53; UTC

Rinkos pokalbiai

Argentine Sovereign Debt Seen as Attractive -- Market Talk

2025-10-08 15:44; UTC

Įsigijimai, susijungimai, perėmimai

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

2025-10-08 15:44; UTC

Įsigijimai, susijungimai, perėmimai

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

2025-10-08 15:43; UTC

Įsigijimai, susijungimai, perėmimai

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

2025-10-08 15:42; UTC

Įsigijimai, susijungimai, perėmimai

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Ocugen Inc Prognozė

Kainos tikslas

By TipRanks

367.03% į viršų

12 mėnesių prognozė

Vidutinis 8.5 USD  367.03%

Aukščiausias 15 USD

Žemiausias 4 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ocugen Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

4

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

0.6818 / 0.74Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

No Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
help-icon Live chat